Response rates of the combination therapy increasing from 20% to 40%.
The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.
Nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits.
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.
BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
World Kidney Day 2017 promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Added progression-free survival and prolonged overall survival possible, according to investigators.
Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.
Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.
In a pilot study, metabolomic analyses of serum and urine showed a high level of predictive ability.
All patients with an SRM should be considered for a biopsy when the results may alter management.
The most common types of benign pathology were oncocytoma, angiomyolipoma, and complex cysts.
In a study, only 3 of 108 patients experienced complications, all of which were minor and required no hospitalization or further intervention.
Adjuvant treatments for RCC must be prioritized by physicians because ultimately value is determined by how medicine is practiced.
In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.
Partial and radical nephrectomy were associated with similar cancer-specific and overall survival in elderly patients.
In the 15 patients in the study, the dual treatment controlled tumors in 93% of the patients, who had either clear cell or papillary renal cell cancer.
Cancer patients diagnosed in their teens had a more than 4-fold higher risk of death from cardiac disease than patients who didn't have cancer.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Not All High-Risk Prostate Cancers Are the Same
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)